HSV-1 US11 MEDIATED EVASION OF HOST SHUTOFF

指导临床科学家发展奖将提供机会，以扩大申请人的密集的分子病毒学培训，并发展在蛋白质生物化学和细胞生物学的专业知识。 这些技能将使申请人成为一个完全独立的研究科学家，并解决解剖病毒感染和人类疾病的分子和遗传基础的研究。 指导这次培训的导师是单纯疱疹病毒学专家。 候选人的职业目标是成为一名儿科医生-科学家，提供病毒发病机制的见解，最终将改善病毒感染患者的治疗和管理决策。申请人的研究兴趣集中在病毒发病机制的分子和遗传基础上：具体来说，病毒如何逃避宿主内在和免疫防御系统。该提案研究了无毒疱疹病毒中的第二位点突变如何使后代重新获得其致病潜力并逃避细胞内宿主防御系统，干扰素诱导的蛋白激酶（PKR）。 研究已经确定，位于第二位点突变（US 11）侧翼的HSV基因的动力学表达的变化有助于这些病毒的新致病性。 这些研究没有解决一个重要的悖论：US 11蛋白的早期合成使病毒能够逃避PKR，但病毒携带的预制蛋白是无效的。该建议的工作假设是，虽然PKR抑制的这些功能差异可能反映了预制和合成的US 11之间的固有生物化学差异，但这更可能反映了合成的US 11募集辅助感染细胞蛋白的相对能力。将使用生化技术（色谱法、2-D电泳、体内磷酸化）分离和分析病毒体相关和合成的US 11。 随后将使用PKR体外激酶试验检测功能差异。 使用生物化学（免疫沉淀，蛋白质亲和力）和遗传学方法（酵母双杂交系统）的亲和力研究将评估US 11或PKR是否招募参与改变PKR途径的感染细胞蛋白。体外PKR激酶测定将测试所鉴定的蛋白质的功能意义。 最后，将通过创建表达US 11的细胞系和用无毒病毒鉴定的基因并检查表型变化来评价生物学功能。

The Mentored Clinical Scientist Development Award will provide the opportunity to extend the applicant's intensive molecular virology training and develop an expertise in protein biochemistry and cellular biology. These skills will enable the applicant to become a fully independent research scientist and to address studies that dissect the molecular and genetic basis of viral infection and human disease. The mentor who will direct this training is an expert in herpes simplex virology. The candidate's career objective is to become a pediatrician- scientist who provides insights into viral pathogenesis which ultimately will improve the therapeutic and management decisions for patients with viral infections. Research interests of the applicant focus on the molecular and genetic basis for viral pathogenesis: specifically, how viruses evade intrinsic and immune host defense systems. This proposal examines how second-site mutations in avirulent herpesviruses enable progeny to reacquire their pathogenic potential and evade an intracellular host defense system, the interferon induced protein kinase (PKR). Studies have identified that a change in the kinetic expression of an HSV gene flanking the second site mutations (US11) contributes to the renewed pathogenicity of these viruses. These studies have not resolved a significant paradox: the early synthesis of US11 protein enables viral evasion of PKR but pre-made protein carried in with the virus is ineffective. The working hypothesis of this proposal is that while these functional differences in PKR inhibition may reflect inherent biochemical differences between the pre-made and synthesized US11, it is more likely that this reflects the relative ability of synthesized US11 to recruit accessory infected cell proteins. Biochemical techniques (chromatography, 2-D electrophoresis, in vivo phosphorylation) will be used to isolate and analyze virion-associated and synthesized US11. This will be followed by tests for functional differences using a PKR in vitro kinase assay. Affinity studies using both biochemical (immunoprecipitation, protein affinity) and genetic methods (yeast two hybrid system) will evaluate if US11 or PKR recruit participating infected cell proteins that modify the PKR pathway. An in vitro PKR kinase assay will test the functional significance of the identified proteins. Finally, biologic function will be evaluated by creating a cell line expressing the US11 and identified gene with an avirulent virus and examining for phenotypic changes.